TPN-101 in Aicardi-Goutières Syndrome (AGS)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Aicardi-Goutières Syndrome (AGS)
Interventions
DRUG

TPN-101

100 mg/ day up to 400mg/day of TPN-101

Trial Locations (5)

20154

SST Fatebenefratelli Sacco, Milan

25123

Presidio Ospedale dei Bambini [Children's Hospital], Brescia

27100

Istituto Neurologico Casimiro Mondino, Pavia

75015

Laboratory of Neurogenetics and Neuroinflammation Imagine Institute - INSERM U1163, Paris

EH9 1LF

Royal Hospital for Children and Young People, Edinburgh

All Listed Sponsors
lead

Transposon Therapeutics, Inc.

INDUSTRY